Don’t undermine the system that incentivized GLP-1 development
March 16, 2026
Washington Times
A left-leaning pressure group recently sent a letter to Health and Human Services Secretary Robert F. Kennedy Jr. asking his agency to rescind the patent rights earned by the developers of GLP-1 drugs. Some 12% of U.S. adults have taken these medications.
Rescinding the patents is a dangerous idea that would reduce our health and well-being.
GLP-1 medications benefit patients with various conditions. They have become a popular weight loss drug that suppresses people’s appetites and helps patients living with Type 2 diabetes better control their blood sugar levels. They reduce the risks of heart attacks and strokes and have the potential to help patients living with addiction and neurodegenerative diseases.
Read More